Return to homepagePandemic Pact

Use of PDE5 Inhibitor for Preventing Cardiac Damage by SARS-CoV-2 in COVID-19 Patients with Cardiopulmonary Diseases

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    University of Minnesota

  • Principal Investigator

    PhD. Bong Sook Jhun

  • Research Location

    United States of America

  • Lead Research Institution

    Medical School, University of Minnesota

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Led by Bong Sook Jhun, PhD, assistant professor of medicine, researchers in this study will explore why COVID-19 patients with pre-existing PAH have a lower risk for severe illness and death, despite the fact that patients with general cardiopulmonary disease have a significantly higher risk. They will also assess whether they can use clinically approved PAH-specific medications to mitigate the increased risk of death in COVID-19 patients with other cardiovascular diseases. "It is likely that some of the medications targeted to treat PAH play a protective role during SARS-CoV-2 infection, potentially by blocking host-cell injury in the cardiopulmonary system," said Jhun. "Our project may provide clues to understand the cardiovascular impact of COVID-19 and lead to new treatment strategies to reduce the cardiac risks in COVID-19 patients with pre-existing cardiopulmonary disease."